Fig. 3
Distribution of participants by (a) BMI percentile and (b) BMI categories at the initiation of LUM/IVA therapy and at 24 months (LUM/IVA: lumacaftor/ivacaftor).
Fig. 3 | Scientific Reports
Distribution of participants by (a) BMI percentile and (b) BMI categories at the initiation of LUM/IVA therapy and at 24 months (LUM/IVA: lumacaftor/ivacaftor).
